5th annual conference on cytokines and inflammation 29-30 January 2007, Breckenridge, Colorado, USA.
The concept of anticytokine therapies for the treatment of inflammatory diseases has been proven with the successful launch of therapeutics targeting TNF and IL-1, and with numerous additional anticytokine strategies in development. The 5th annual conference on Cytokines and Inflammation provided a timely update on this topic with sections devoted to cytokine biology, chemokines, new technologies for cytokine-based therapy and small-molecule agonists and antagonists. This brief review summarizes key findings from the conference.
Numerof
Robert P
RP
Inflammation and Immunology Therapeutic Research Group, Bayer HealthCare Pharmaceuticals, 2600 Hilltop Drive, PO Box 4099, Richmond, CA 94804-0099, USA. robert.numerof@bayer.com
Blasko
Eric
E
D000818:Animals; D000906:Antibodies / Q000276:immunology; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000276:immunology; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology
D000906:Antibodies; D016207:Cytokines